Reply: ‘Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer’

Álvarez, Rafael; Musteanu, Mónica; García-García, Elena; López-Casas, Pedro P.; Megı́as, Diego; Guerra, Carmen; Muñoz, Manuel; Quijano, Yolanda; Cubillo, Antonio; Rodríguez-Pascual, Jesús; Plaza, Carlos; Vicente, Emilio; Prados, Susana; Tabernero, Susana; Barbacid, Mariano; López‐Ríos, Fernando; Hidalgo, Manuel

doi:10.1038/bjc.2014.129

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an active state, PSCs exhibit enhanced ECM production and can be identified by expression of α-smooth muscle actin (SMA). Using SMA as a marker, studies have shown that increased PSC activation was associated with shorter overall survival in PDA patients [4–6], supporting the concept that the ECM is an active and vital component of the tumor microenvironment.…”

Section: Introductionmentioning

confidence: 94%

Matrix control of pancreatic cancer: New insights into fibronectin signaling

Topalovski

Brekken

2016

Cancer Letters

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDA) is a highly metastatic disease that resists most current therapies. A defining characteristic of PDA is an intense fibrotic response that promotes tumor cell invasion and chemoresistance. Efforts to understand the complex relationship between the tumor and its extracellular network and to therapeutically perturb tumor-stroma interactions are ongoing. Fibronectin (FN), a provisional matrix protein abundant in PDA stroma but not normal tissues, supports metastatic spread and chemoresistance of this deadly disease. FN also supports angiogenesis, which is required for even hypovascular tumors such as PDA to develop and progress. Targeting components of the tumor stroma, such as FN, can effectively reduce tumor growth and spread while also enhancing delivery of chemotherapy. Here, we review the molecular mechanisms by which FN drives angiogenesis, metastasis and chemoresistance in PDA. In light of these new findings, we also discuss therapeutic strategies to inhibit FN signaling.

show abstract

Section: Introductionmentioning

confidence: 94%